This is a multicenter, observational, prospective, real-life study that will be conducted at Headache Centers, aimed at confirming the efficacy and safety of the combination of sumatriptan 85 mg with naproxen 500 mg. The combination of sumatriptan 85 mg and naproxen sodium 500 mg is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients for whom sumatriptan monotherapy is insufficient. In two randomized studies, the sumatriptan/naproxen sodium combination demonstrated significantly greater efficacy (65% of participants-n=1461-reported pain freedom at 2 hours) compared to sumatriptan alone (55%), naproxen sodium alone (44%), or placebo (28%) when used as a late therapy for a single migraine episode in adults. Similar results were observed in a second study (n=1495), with 57% of participants achieving pain freedom within 2 hours after taking the sumatriptan/naproxen sodium combination, outperforming both sumatriptan monotherapy (50%) and naproxen sodium monotherapy (43%), as well as placebo (29%). This superiority was further assessed through sustained pain freedom over 24 hours, with an efficacy of 23-25% in participants treated with the sumatriptan/naproxen combination compared to placebo (7-8%; p<0.001 for both studies) and its individual components (sumatriptan monotherapy: 14%-16%; p=0.009 and p<0.001, naproxen sodium monotherapy: 10%).
In four additional randomized studies, the combination was also found to be effective in menstrual migraine and dysmenorrhea, as well as in cases of poor response or intolerance to triptan therapy. In clinical trials, sumatriptan/naproxen sodium was generally well tolerated, with an overall safety profile similar to that of sumatriptan. The most common adverse events were consistent with those expected for sumatriptan and naproxen sodium.

开始日期2025-04-10

申办/合作机构

IRCCS San Raffaele Roma Srl

CTR20222831

/ CompletedN/A

康缘华威医药有限公司研制的琥珀酸舒马普坦萘普生钠片与持证商为Currax Pharmaceuticals LLC公司的琥珀酸舒马普坦萘普生钠片（商品名：Treximet®）在中国健康受试者中进行的随机、开放、单剂量、两周期、双交叉、空腹及餐后状态下的生物等效性研究

以康缘华威医药有限公司研制的琥珀酸舒马普坦萘普生钠片（规格：85/500 mg，以舒马普坦/萘普生钠计）为受试制剂，以持证商为Currax Pharmaceuticals LLC公司的琥珀酸舒马普坦萘普生钠片（商品名：Treximet®，规格：85/500 mg，以舒马普坦/萘普生钠计）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；同时评价两种制剂在健康人体中的安全性和耐受性。

开始日期2022-11-08

申办/合作机构

康缘华威医药有限公司

CTR20181317

/ CompletedN/A

舒马普坦萘普生钠片（85/500mg）在健康受试中随机、开放、单剂量、两周期、双交叉空腹和餐后的人体生物等效性研究

以康缘华威医药有限公司研制的舒马普坦萘普生钠片（规格：85/500mg）为受试制剂，Pernix Ireland Limited公司生产的舒马普坦萘普生钠片（商品名：Treximet；规格：85/500mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。

开始日期2018-08-16

申办/合作机构

南京华威医药科技集团有限公司

100 项与萘普生钠/琥珀酸舒马普坦相关的临床结果

登录后查看更多信息

100 项与萘普生钠/琥珀酸舒马普坦相关的转化医学

登录后查看更多信息

100 项与萘普生钠/琥珀酸舒马普坦相关的专利（医药）

登录后查看更多信息

项与萘普生钠/琥珀酸舒马普坦相关的文献（医药）

2016-01-01·Drugs1区 · 医学

Sumatriptan/Naproxen Sodium: A Review in Migraine

1区 · 医学

Review

作者: Syed, Yahiya Y

Sumatriptan/naproxen sodium (Treximet®) is a fixed-dose combination of a serotonin 5-HT1B/1D receptor agonist (sumatriptan) and an NSAID (naproxen sodium), approved in the USA for the acute treatment of migraine with or without aura in adolescents and adults. In a randomized, phase 3 trial in adolescents, significantly more sumatriptan/naproxen sodium than placebo recipients were pain-free at 2 h. Similarly, in a pair of randomized phase 3 trials in adults, significantly more sumatriptan/naproxen sodium than placebo recipients had relief from migraine symptoms at 2 h, and the combination was more effective than individual components in terms of sustained (2-24 h) pain-free response rate. Sumatriptan/naproxen sodium was generally well tolerated, with ≤11 % of adolescents and ≤22 % of adults reporting treatment-related adverse events in the key clinical trials. The most common adverse reactions were nasopharyngitis, hot flushes and muscle tightness in adolescents, and dizziness, pain or pressure sensations, nausea, somnolence, dry mouth, dyspepsia and paraesthesia in adults. Based on current data, sumatriptan/naproxen sodium is a useful option for the acute treatment of migraine in adolescents and adults. The fixed-dose combination may reduce pill burden and improve adherence in some patients.

2015-05-01·Therapeutic innovation & regulatory science4区 · 医学

Medication Guide Reading Behaviors and Attitudes Among Subjects With Migraine, Asthma, or COPD

4区 · 医学

Article

作者: Hinds, David ; DiSantostefano, Rachael L ; Bibeau, Kristen B

BACKGROUND:

This cross-sectional survey describes attitudes and reading behaviors toward medication guides among 785 subjects with migraine, asthma, or COPD who reported recent use of Treximet (sumatriptan/naproxen sodium) or Advair (fluticasone propionate/salmeterol).

RESULTS:

The survey demonstrated that the majority (82%) of subjects had read their medication guide, but most read it exactly once and did not read it thoroughly. Patients did not read medication guides with each refill, with the most frequent reasons being that they did not expect the information to have changed and that a doctor would tell them what they needed to know. Factors significantly associated with patients hypothetically being more likely to read medication guides associated with their new prescription included increasing age, simplification to format and content of the medication guide, and where subjects typically received their medication safety information. Patients reported acquiring medication safety from doctors or pharmacists more frequently than from medication guides.

CONCLUSIONS:

The results provide insights into potential revisions to the medication guides that may improve reading behaviors.

2014-07-01·Headache2区 · 医学

Final Results From the 16‐Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry

2区 · 医学

Article

作者: Sinclair, Susan M. ; Ephross, Sara A.

Objectives:

To monitor for a signal of major teratogenicity by determining the risk of all birth major defects following in utero exposure to sumatriptan, naratriptan, and the sumatriptan/naproxen sodium combination product (tablets marketed in the United States as Treximet [GlaxoSmithKline, Research Triangle Park, NC, USA]), and to monitor for unusual patterns of defects that might suggest teratogenicity.

Background:

The prevalence of migraine is highest in women of childbearing age. Coupled with the recurrent nature of migraine attacks and the high proportion of unplanned pregnancies, intentional and inadvertent exposure to anti‐migraine drugs in pregnancy is likely. The Sumatriptan, Naratriptan, and Treximet Pregnancy Registry captured data on women exposed to those drugs during pregnancy to monitor for evidence of major teratogenicity.

Methods:

In this primarily prospective, observational study, health care professionals from anywhere in the world enrolled, on a voluntary basis, women exposed to sumatriptan, naratriptan, or the sumatriptan/naproxen sodium combination product during their pregnancies. Only pregnancies with unknown outcomes at the time of enrollment were included in the analysis. The proportion of infants or fetuses with major birth defects was calculated as the total number of infants/fetuses with major birth defects divided by the sum of the number of infants/fetuses with major birth defects + the number of live births without defects. The risk of major birth defects was further stratified by earliest trimester of pregnancy exposure.

Results:

The registry enrolled 680 evaluable exposed pregnant women, which resulted in 689 infants and fetuses (outcomes). Of these outcomes, 626 were exposed to sumatriptan, 57 were exposed to naratriptan (seven were exposed to both sumatriptan and naratriptan), and six were exposed to the sumatriptan/naproxen sodium combination product. Twenty outcomes with major birth defects were reported among 528 outcomes exposed in the first trimester to sumatriptan. The estimated risk of major birth defects following first‐trimester sumatriptan exposure is 4.2% (20/478 [95% confidence interval [CI] 2.6%–6.5%]). Among 52 first‐trimester exposures to naratriptan, major birth defects were reported in one outcome, an infant with exposure to both sumatriptan and naratriptan [birth defect risk of 2.2% (1/46 [95% CI 0.1%–13.0%]). No major defects were reported among the five outcomes with first‐trimester exposure to the sumatriptan/naproxen sodium combination products.

Conclusions:

The Sumatriptan, Naratriptan, and Treximet Pregnancy Registry detected no signal of teratogenicity associated with major birth defects for sumatriptan. This finding is consistent with results from other observational studies using a variety of control groups. Enrollment in the registry was insufficient to permit definitive conclusions of the risks associated with naratriptan or sumatriptan/naproxen sodium tablets, or to assess the risk of individual birth defects in any of the products studied. Low enrollment and high rates of loss to follow up within the registry over an extended period of time led the registry's scientific advisory committee to conclude that continuation of the registry beyond its 16 years would offer little additional power to rule out more moderate increases in the risk of birth defects. Data from the other ongoing surveillance sources constitute an important element of post‐marketing surveillance of these medications. The lack of a signal of major teratogenicity with sumatriptan across these several sources of data is encouraging.

项与萘普生钠/琥珀酸舒马普坦相关的新闻（医药）

2025-05-29

·摩熵医药

40+亿大市场，康缘药业首仿获批上市！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。5月27日，国家药品监督管理局（NMPA）发布通知显示，康缘药业研发的舒马普坦萘普生钠片获批上市，用于成人和12岁及以上儿童患者有或无先兆偏头痛的急性治疗，为国内首仿。截图来源：摩熵医药一致性评价数据库舒马普坦萘普生钠片包含血清素受体1B/血清素受体1D（5-HT1B/5-HT1D）激动剂舒马普坦和环氧合酶（COX）抑制剂萘普生两种活性成分，由Pozen（Aralez Pharmaceuticals）和葛兰素史克（GSK）合作研发，于2008年在美国获批上市，商品名为Treximet。原研药未在国内获批上市。据摩熵医药-中国药品审评库显示，目前尚无其他厂家研发。美国FDA黑框警告：严重心血管和胃肠道事件的风险，禁用于冠状动脉旁路移植术(CABG)手术。葛兰素史克的琥珀酸舒马普坦萘普生钠片2016年全球销售额为4.45亿元。2022年全球偏头痛市场的整体价值为96亿美元，预计2027年将达到175亿美元，复合年增长率为9.4%，市场前景良好。据摩熵医药-销售数据库显示，偏头痛在全国医院（全终端）2023年销售额为44.33亿元，2024上半年为22.34亿元。其中大部分为中药，如养血清脑颗粒、天麻素注射液、氢溴酸樟柳碱注射液。截图来源：摩熵医药-销售数据库END本文为原创文章，转载请留言获取授权近期热门资源获取数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-2025042023H2-2024H1中国药品分析报告-2025042024年中国1类新药靶点白皮书-202503中国AI医疗健康企业创新发展百强榜单-202502解码护肤抗衰：消费偏好洞察与市场格局分析-2025022024年FDA批准上市的新药分析报告-2025012024年NMPA批准上市的新药分析报告-2025012024年医保谈判及市场分析报告-2025.012024年中国医疗健康投融资全景洞察报告-202501小分子化药白皮书（上）-2025012024医美注射材料市场发展分析报告-202412中国放射性药物产业白皮书-202410近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准一致性评价医药出海

2025-05-28

·医药魔方Info

康缘药业一款首仿药获批，治疗偏头痛

5月27日，国家药监局官网显示，康缘药业的舒马普坦萘普生钠片仿制药获批，用于急性治疗有或无先兆的偏头痛发作。这是首个上市的舒马普坦萘普生钠片仿制药。原研舒马普坦萘普生复方由Pozen（Aralez Pharmaceuticals）和葛兰素史克（GSK）合作研发，包含血清素受体1B/血清素受体1D（5-HT1B/5-HT1D）激动剂舒马普坦和环氧合酶（COX）抑制剂萘普生两种活性成分，于2008年在美国获批上市，商品名为Treximet。原研药未在国内获批上市。据医药魔方PharmaGO数据库，国内仅康缘药业一家申报了舒马普坦萘普生复方仿制药。Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

上市批准

2025-03-11

·PRNewswire

Currax Pharmaceuticals: Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA®

BRENTWOOD, Tenn., March 11, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion HCl), today announced the publication of its Cardiovascular Health Outcomes Analysis (HOA) for CONTRAVE®/MYSIMBA® in Obesity Pillars, the official journal of the Obesity Medicine Association. This peer-reviewed study, based on electronic health record data from more than 24,600 patients followed for over 4.7 years, found no evidence of excess cardiovascular risk and no statistically significant difference in major adverse cardiovascular events (MACE) between CONTRAVE/MYSIMBA and the comparator drug. The study's publication provides important real-world evidence that further substantiates the cardiovascular safety profile of CONTRAVE/MYSIMBA building on findings from prior clinical trials, a systemic literature review, two published FDA Adverse Event Reporting System (FAERS) database studies, and over ten years of post-marketing safety surveillance. These results provide valuable insights to support regulatory and clinical decision-making in the treatment of obesity. "The publication of this analysis in Obesity Pillars underscores the utility of evaluating long-term cardiovascular outcomes in routine clinical practice," said Michael Kyle, M.D., SVP, Chief Medical Officer of Currax Pharmaceuticals. "The findings further substantiate the cardiovascular safety profile of CONTRAVE/MYSIMBA, aligning with previous clinical and observational studies." CONTRAVE, approved in the U.S. and marketed in Europe as MYSIMBA, has been studied extensively in both randomized clinical trials and observational settings. The latest analysis builds upon prior research, including the LIGHT trial, and complements the ongoing INFORMUS trial, a large-scale cardiovascular outcomes study, which now has enrolled more than 3,000 patients and is designed to meet regulatory post-marketing requirements to further characterize long-term cardiovascular safety. "Obesity is a serious chronic disease, and it's critical that healthcare professionals have access to rigorous, data-driven evidence when considering treatment options," said George Hampton, President and CEO of Currax Pharmaceuticals. "Currax continues to invest in clinical trials designed to increase the utility of Contrave for physicians treating obesity." The full study is available in Obesity Pillars: About Currax Pharmaceuticals LLC Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on tackling the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit . WHAT IS CONTRAVE? Along with diet and exercise, CONTRAVE is a prescription weight-loss medicine that may help some adults with a BMI > 30 kg/m2 (obese) or with a BMI of > 27 kg/m2 (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off. It is not known if CONTRAVE changes your risk of heart problems or stroke or of death due to heart problems or stroke. It is not known if CONTRAVE is safe and effective when taken with other prescription, over-the-counter, or herbal weight-loss products. CONTRAVE is not approved to treat depression or other mental illnesses, or to help people quit smoking (smoking cessation). IMPORTANT SAFETY INFORMATION CONTRAVE can cause serious side effects including: Suicidal thoughts or actions: One of the ingredients in CONTRAVE is bupropion. Bupropion has caused some people to have suicidal thoughts or actions or unusual changes in behavior, whether or not they are taking medicines used to treat depression. Bupropion may increase the risk of suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. If you already have depression or other mental illnesses, taking bupropion may cause it to get worse, especially within the first few months of treatment. While taking CONTRAVE, you or your family members should pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when you start taking CONTRAVE or when your dose changes. Stop taking CONTRAVE and call a healthcare provider right away if you or your family members notice any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempts to commit suicide; depression; anxiety; feeling agitated or restless; panic attacks; irritability; aggression, anger, or violence; acting on dangerous impulses; an extreme increase in activity and talking; other unusual changes in behavior or mood; trouble sleeping. CONTRAVE is not approved for use in children under the age of 18. Do not take CONTRAVE if you have uncontrolled high blood pressure; have or have had seizures; use other medicines that contain bupropion such as WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN; have or have had an eating disorder called anorexia or bulimia; are dependent on opioid pain medicines or use medicines to help stop taking opioids, or are in opiate withdrawal; drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these make you sleepy), benzodiazepines, or anti-seizure medicines and stop using them all of a sudden; are taking or have taken medicines called monoamine oxidase inhibitors (MAOIs) in the past 14 days; or are allergic to any of the ingredients in CONTRAVE. Tell your healthcare provider about all of your medical conditions including if you have: depression or other mental illnesses; attempted suicide; seizures; head injury; tumor or infection of brain or spine; low blood sugar or low sodium; liver or kidney problems; high blood pressure; heart attack, heart problems, or stroke; eating disorder; drinking a lot of alcohol; prescription medicine or street drug abuse; are 65 or older; diabetes; pregnant or planning to become pregnant; or breastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. CONTRAVE may cause serious side effects, including: Seizures. There is a risk of having a seizure when you take CONTRAVE. The risk of seizure is higher in people who take higher doses of CONTRAVE, have certain medical conditions, or take CONTRAVE with certain other medicines. Do not take any other medicines while you are taking CONTRAVE unless your healthcare provider has said it is okay to take them. If you have a seizure while taking CONTRAVE, stop taking CONTRAVE and call your healthcare provider right away. Risk of opioid overdose. Do not take large amounts of opioids, including opioid-containing medicines, such as heroin or prescription pain pills, to try to overcome the opioid-blocking effects of naltrexone. This can lead to serious injury, coma, or death. Get emergency medical help right away if you take opioids and you: have trouble breathing become very drowsy with slowed breathing have slow, shallow breathing feel faint, very dizzy, confused, or have unusual symptoms Sudden opioid withdrawal. People who take CONTRAVE must not use any type of opioid including street drugs, prescription pain medicines, cough, cold, or diarrhea medicines that contain opioids, or opioid dependence treatments, for at least 7 to 10 days before starting CONTRAVE. Using opioids in the 7 to 10 days before you start taking CONTRAVE may cause you to suddenly have symptoms of opioid withdrawal when you take it. Sudden opioid withdrawal can be severe, and you may need to go to the hospital. Tell your healthcare provider you are taking CONTRAVE before a medical procedure or surgery. Severe allergic reactions. Stop taking CONTRAVE and call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of an allergic reaction: rash, itching, hives, fever, swollen lymph glands, painful sores in your mouth or around your eyes, swelling of your lips or tongue, chest pain, or trouble breathing. Increases in blood pressure or heart rate. Some people may get high blood pressure or have a higher heart rate when taking CONTRAVE. Your healthcare provider should check your blood pressure and heart rate before you start taking, and while you take CONTRAVE. Liver damage or hepatitis. Stop taking CONTRAVE and tell your healthcare provider if you have any of the following symptoms of liver problems: stomach area pain lasting more than a few days, dark urine, yellowing of the whites of your eyes, or tiredness. Your healthcare provider may need to stop treating you with CONTRAVE if you get signs or symptoms of a serious liver problem. Manic episodes. Bupropion can cause some people who were manic or depressed in the past to become manic or depressed again. Visual problems (angle-closure glaucoma). Signs and symptoms may include: eye pain, changes in vision, swelling or redness in or around the eye. Talk with your healthcare provider to find out if you are at risk for angle-closure glaucoma and to get treatment to prevent it if you are at risk. Increased risk of low blood sugar in people with type 2 diabetes mellitus who also take medicines to treat their diabetes (such as insulin or sulfonylureas). You should check your blood sugar before you start taking CONTRAVE and while you take CONTRAVE. The most common side effects of CONTRAVE include nausea, constipation, headache, vomiting, dizziness, trouble sleeping, dry mouth, and diarrhea. These are not all of the possible side effects of CONTRAVE. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please see the Full Prescribing Information, including Medication Guide, for CONTRAVE. Media Contact [email protected] SOURCE Currax Pharmaceuticals LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准临床结果

100 项与萘普生钠/琥珀酸舒马普坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	萘普生钠/琥珀酸舒马普坦	N02C	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Currax Pharmaceuticals LLC	2008-04-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	临床3期	中国	-	2018-04-27
急性偏头痛	临床3期	美国	GSK Plc	2006-09-13
无先兆偏头痛	临床3期	美国	GSK Plc	2006-09-01
痛经	临床3期	美国	GSK Plc	2006-05-01
头痛	临床3期	美国	GSK Plc	2005-10-01
婴儿痉挛	临床3期	美国	GSK Plc	2005-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01086358 (CTgov)	临床4期	偏头痛	60	almotriptan+eletriptan+Treximet+rizatriptan+sumatriptan+zolmitriptan+triptan (Arm 1 - Triptan)	淵積鹽積選鬱夢顧廠糧(繭繭顧夢鬱鹹觸餘夢繭) = 鹽餘蓋網襯衊網製淵簾獵製鑰獵範淵鏇選壓衊 (餘壓積獵襯繭鏇遞製顧, 夢顧選鏇憲壓觸鬱積鑰 ~ 廠築淵築壓糧廠製製製) 更多	-	2018-05-01
				Naproxen Sodium (Treximet)+Sumatriptan (Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm)	淵積鹽積選鬱夢顧廠糧(繭繭顧夢鬱鹹觸餘夢繭) = 衊鑰憲膚憲齋繭築繭願獵製鑰獵範淵鏇選壓衊 (餘壓積獵襯繭鏇遞製顧, 鑰遞憲蓋積積餘獵衊蓋 ~ 糧壓築鏇鏇構範餘廠窪) 更多
NCT00385008 (CTgov)	临床3期	急性偏头痛	20	Naproxen+TREXIMA+Sumatriptan (TREXIMA (Sumatriptan 85 mg + Naproxen 500 mg))	鑰鏇鬱齋膚艱膚遞醖鹽(遞積窪鑰願築網膚簾願) = 壓鑰簾鬱顧遞鑰壓衊網淵構醖膚簾鏇範構構艱 (網衊廠構顧窪鹹網築簾, 顧鏇願簾網願糧膚廠衊 ~ 夢糧願顧艱繭艱糧醖鏇) 更多	-	2018-02-12
				Eletriptan (Relpax (Eletriptan 40 mg))	餘憲醖窪觸獵鑰觸窪廠(簾築淵夢糧醖壓夢糧繭) = 齋簾顧製鏇繭夢膚廠壓遞憲醖選觸選蓋醖壓選 (窪鹹積壓窪築遞襯鬱夢, 衊選顧廠夢網觸艱鹽製 ~ 範繭遞醖憲壓鏇糧積衊) 更多
NCT01329562 (CTgov)	临床4期	偏头痛	41	Placebo (Placebo)	網願觸糧構衊築構夢顧 = 壓糧衊廠壓糧遞簾鹽膚網簾壓襯鹽鑰鑰鹹齋構 (獵遞齋淵膚繭觸鑰鏇廠, 淵蓋糧夢鏇廠獵鏇鏇窪 ~ 鹹夢蓋餘齋齋遞鑰遞觸) 更多	-	2014-04-09
				Treximet (Treximet)	網願觸糧構衊築構夢顧 = 鏇廠窪積簾窪築觸淵衊網簾壓襯鹽鑰鑰鹹齋構 (獵遞齋淵膚繭觸鑰鏇廠, 壓鏇繭艱壓醖鬱餘願醖 ~ 廠憲鹹獵鹹淵積膚繭膚) 更多
NCT01053507 (CTgov)	临床4期	认知功能障碍 \| 创伤后头痛	23	sumatriptan/naproxen sodium (Treximet)	鑰窪衊範選窪憲艱鏇範(齋積衊襯蓋鬱餘製觸醖) = 蓋衊窪積願構憲蓋艱製膚淵觸獵遞淵鑰鹽窪製 (夢積淵窪膚鹽壓鹽淵選, 7.6) 更多	-	2014-03-10
				Placebo (Placebo)	鑰窪衊範選窪憲艱鏇範(齋積衊襯蓋鬱餘製觸醖) = 夢衊鏇簾鑰艱構構鬱鹹膚淵觸獵遞淵鑰鹽窪製 (夢積淵窪膚鹽壓鹽淵選, 5.3) 更多
NCT01090050 (CTgov)	临床4期	偏头痛	56	Sumatriptan/Naproxen Sodium (Sumatriptan/Naproxen Sodium)	夢積築選憲鬱鏇衊鏇鹹(鏇顧鏇築顧鑰餘鑰艱顧) = 壓艱簾鬱顧衊廠積鏇醖網鑰膚糧醖構膚鑰築鬱 (觸醖淵衊壓遞膚蓋艱網, 32.9) 更多	-	2013-07-03
				Naproxen Sodium (Naproxen Sodium)	夢積築選憲鬱鏇衊鏇鹹(鏇顧鏇築顧鑰餘鑰艱顧) = 選夢醖範糧網膚淵簾築網鑰膚糧醖構膚鑰築鬱 (觸醖淵衊壓遞膚蓋艱網, 36.2) 更多
NCT01300546 (CTgov)	临床4期	偏头痛	40	Sumatriptan/Naproxen Sodium (Sumatriptan/Naproxen Sodium)	夢遞廠襯廠蓋醖壓鬱獵(壓蓋鹹構鏇憲襯廠願齋) = 襯鏇衊蓋構遞積壓製範獵糧製鬱獵鏇衊淵範鏇 (積蓋鹽範獵獵鬱壓範廠, 34.80) 更多	-	2013-05-21
				Naproxen Sodium (Naproxen Sodium)	夢遞廠襯廠蓋醖壓鬱獵(壓蓋鹹構鏇憲襯廠願齋) = 鏇觸願壓襯願壓構鏇憲獵糧製鬱獵鏇衊淵範鏇 (積蓋鹽範獵獵鬱壓範廠, 36.48) 更多
NCT00573170 (Pubmed \| Headache)	临床3期	急性偏头痛	442	SumaRT/Nap (sumatriptan and naproxen combination medication)	鏇製顧蓋構簾壓夢膚選(淵鹹鏇廠鹽艱觸襯鏇窪) = 網獵構鏇選願憲製觸選鹽獵餘範窪簾淵繭鑰憲 (艱繭鹽淵醖鏇範選鬱選 )	-	2012-04-01
				BCM (butalbital-containing combination medication)	鏇製顧蓋構簾壓夢膚選(淵鹹鏇廠鹽艱觸襯鏇窪) = 艱願鬱獵製蓋窪憲構範鹽獵餘範窪簾淵繭鑰憲 (艱繭鹽淵醖鏇範選鬱選 )
NCT00843024 (107979, CTgov)	临床3期	偏头痛	589	Placebo	艱鬱夢顧糧獵淵獵醖襯 = 獵憲夢夢觸鏇膚網窪壓淵蓋鹹鹹鬱餘構網遞觸 (糧衊廠顧網鑰鬱衊膚築, 構顧窪鹹窪襯餘願構餘 ~ 網範襯願夢衊願網構積) 更多	-	2011-05-09
NCT00792636 (CTgov)	临床4期	偏头痛	407	sumatriptan tablet	鹹觸糧製製鑰廠憲廠製(廠積蓋觸構遞網遞鏇製) = 鏇蓋糧選廠齋衊襯廠網齋齋醖顧獵簾膚膚膚築 (憲廠壓網積鑰襯觸網窪, 9.15) 更多	-	2010-11-04
NCT00387881 (CTgov)	临床3期	无先兆偏头痛 \| 头痛	679	Placebo	鬱廠鹹衊構艱簾築醖觸 = 蓋醖簾衊遞鑰艱淵遞鹽鬱鹽簾築鏇範簾衊壓夢 (鹹鏇觸鏇製衊鬱糧鬱構, 襯憲衊獵遞壓顧觸衊觸 ~ 鬱選積夢獵鹽願網鬱淵) 更多	-	2009-07-10